AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer
October 29, 2019Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
Deeper patient insights for stronger patient outcomes
October 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing eyeforpharma, pharma
Patient insights are crucial. As you already know, they are the key to the creation of successful, targeted programmes and …
Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome
October 28, 2019Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma
Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships
October 28, 2019Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, pharma, research
The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of …
Ovarian cancer market set to smash $6.7 billion by 2025
October 28, 2019Sales and Marketing Cancer, GlobalData, ovarian cancer, pharma
New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound …
Almost 400 Nigerian medical dispensaries shut down for sub-standard practice
October 28, 2019Manufacturing and Production, Medical Communications, Sales and Marketing Nigeria, pharma
Nigeria has seen almost 400 of its medicine dispensaries shut down over “unethical practices and lack of compliance, it has …
European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia
October 28, 2019Sales and Marketing Astellas, Xospata, leukaemia, pharma
Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …
Seattle Genetics reports topline phase 3 HER2-Positive Breast Cancer Data
October 25, 2019Medical Communications
Seattle Genetics, a strong competitor in the breast cancer space, has reported topline results in its phase 3 study evaluating …
Top Ten most popular articles on Pharmafile.com this week
October 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
It’s another end of the week here at Pharmafile and here we run down our top 10 articles and features …
South West Biosciences to receive £18.5m boost
October 25, 2019BioSciences in the UK has received a massive boost of £18.5 million awarded from the Biotechnology and Biological Sciences Research …
Biogen plans Alzheimer’s drug approval after initial research failure
October 25, 2019Medical Communications
Biogen is planning to seek approval for its experimental drug aducanumab, that could potentially be first to treat Alzheimer’s and …
FlyPharma tackles supply chain challenges and industry best practice at another successful conference
October 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flypharma, pharma
For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges …
Novartis enters license agreement with Pliant Therapeutics for fibrosis assets
October 24, 2019Research and Development
Novartis has signed a collaboration and license agreement with Pliant Therapeutics to develop and commercialise preclinical asset PLN-1474 which is …
Alkermes to axe 160 jobs in cost-cutting restructure
October 24, 2019Sales and Marketing
The Irish biopharma company expects to complete most of the job cuts by end of this year and will take …
Novartis receives EC label update approval for Cosentyx in ankylosing spondylitis
October 24, 2019Research and Development
Novartis has announced that the European Commission has approved a label update for the up-titration of Cosentyx (secukunumab) to 300mg …
Badly implemented electronic systems putting NHS patients at risk
October 24, 2019Business Services
A new report has warned that poorly implemented electronic medication systems in the NHS could potentially lead to fatal medication …
GSK receives wider nod for Zejula as it competes with rival AstraZeneca
October 24, 2019Research and Development
The US FDA has approved GlaxoSmithKline’s Zejula (niraparib) for the use in advanced ovarian, fallopian tube, or primary peritoneal cancer …
Damage control: How will pharma manage the health economic impacts of Brexit?
October 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma
When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …
FDA approves Vertex’s Trikafta in new indication, now potentially covering 90% of cystic fibrosis patients
October 23, 2019Research and Development, Sales and Marketing FDA, Trikafta, Vertex, cystic fibrosis, pharma
The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …
New study shows Prozac no better than placebo in treating autism
October 23, 2019Research and Development
A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
